Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

<< Previous

Bullboard Posts

Next >>

Post by robert345on Jun 01, 2022 11:38am

121 Views

Post# 34723440

$HMTXF common share and warrant meaning elaboration

The recently announced private placement of 15 million units has put the entire OTC in awe, in which each full unit consists of one common share and one purchase warrant, each full warrant entitles the holder to acquire one common share at $0.55 per common share for a period of 24 months from the closing of the deal.

https://www.newsfilecorp.com/redirect/WrjBBuqKvY

<< Previous

Bullboard Posts

Next >>

Options trading in a volatile macro environment